Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Università degli Studi di Brescia
- Target Recruit Count
- 60
- Registration Number
- NCT02060604
- Locations
- 🇮🇹
Spedali Civili di Brescia, Brescia, BS, Italy
Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT02059772
- Locations
- 🇩🇪
Klinik für Augenheilkunde, Klinikum Chemnitz gGmbH, Chemnitz, Germany
Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Federal University of São Paulo
- Registration Number
- NCT02055911
- Locations
- 🇧🇷
Dept of Ophthalmology - UNIFESP/Hospital São Paulo, São Paulo, SP, Brazil
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Aerpio Therapeutics
- Target Recruit Count
- 144
- Registration Number
- NCT02050828
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Biocad
- Registration Number
- NCT02036723
- Locations
- 🇷🇺
Scientific and Research Institute named after Helmholtz, Moscow, Russian Federation
🇷🇺Regional Clinical Ophthalmic Hospital named TI Yeroshevsky, Samara, Russian Federation
🇧🇷Hospital dos Olhos do Paraná, Curitiba, Paraná, Brazil
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT02034006
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 199
- Registration Number
- NCT01994291
- Locations
- 🇺🇸
Retinal Diagnostic Center, Campbell, California, United States
🇺🇸Southern California Desert Retina Consultants, Palm Desert, California, United States
🇺🇸American Institute of Research (Administrative Only), Whittier, California, United States
Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1049
- Registration Number
- NCT01986907
- Locations
- 🇮🇹
Novartis Investigative Site, Pozzuoli, Italy
Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Justis Ehlers
- Target Recruit Count
- 27
- Registration Number
- NCT01982435
- Locations
- 🇺🇸
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Cole Eye Institute at Hillcrest Hospital, Mayfield Heights, Ohio, United States
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
- Conditions
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 349
- Registration Number
- NCT01972789
- Locations
- 🇦🇺
Novartis Investigative Site, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.